Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
882.99B
Market cap882.99B
Price-Earnings ratio
37.09
Price-Earnings ratio37.09
Dividend yield
0.73%
Dividend yield0.73%
Average volume
3.05M
Average volume3.05M
High today
$945.50
High today$945.50
Low today
$851.21
Low today$851.21
Open price
$900.00
Open price$900.00
Volume
8.20M
Volume8.20M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 882.99B, Eli Lilly(LLY) trades at $931.33. The stock has a price-to-earnings ratio of 37.09 and currently yields dividends of 73.2%.

During the trading session on 2026-04-30, Eli Lilly(LLY) shares reached a daily high of $945.50 and a low of $851.21. At a current price of $931.33, the stock is +9.4% higher than the low and still -1.5% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 8.2M, versus its average volume of 3.05M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

Seeking Alpha 1h
Lilly projects 2026 revenue of $82B-$85B and non-GAAP EPS of $35.50-$37 as Foundayo launch begins

Earnings Call Insights Lilly projects 2026 revenue of $82B-$85B and non-GAAP EPS of $35.50-$37 as Foundayo launch begins Apr 30, 2026, 3:12 PM ET Eli Lilly and...

Lilly projects 2026 revenue of $82B-$85B and non-GAAP EPS of $35.50-$37 as Foundayo launch begins
Sherwood News 3h
Eli Lilly quells fears that its GLP-1 pill debut is off to a rocky start

Early prescription data for Foundayo showed the pill was having a lackluster rollout compared to its competitor. Going into its Thursday morning earnings repor...

Eli Lilly quells fears that its GLP-1 pill debut is off to a rocky start
Benzinga 4h
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand

Earnings Overview Shows Strong Growth Eli Lilly reported first-quarter adjusted earnings of $8.55 per share, beating the consensus of $6.66. The company’s sales...

Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand

Analyst ratings

82%

of 34 ratings
Buy
82.4%
Hold
14.7%
Sell
2.9%

More LLY News

TipRanks 5h
Eli Lilly, Novo Nordisk Stocks Jump as FDA Moves Against Bulk Production of Obesity Drug Ingredients

Shares in drugmakers Eli Lilly (LLY) and Novo Nordisk (NVO) climbed on Thursday morning after the U.S. health watchdog proposed not to allow outsourcing facilit...

Nasdaq 5h
Why Eli Lilly Stock Just Popped

Key Points Eli Lilly beat on both top and bottom lines this morning. The company's GLP-1 business is doing fine despite pricing pressure. Now, Lilly is focus...

Why Eli Lilly Stock Just Popped
CNBC 5h
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. The ⁠Food and Drug ⁠Administration on Thursday proposed ​ex...

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
Investor's Business Daily 8h
Eli Lilly Obliterates Sales Forecasts By $2 Billion, Shares Surge

Eli Lilly (LLY) stock bounded higher early Thursday after the pharma titan reported adjusted earnings of $8.55 per share on $19.8 billion in first-quarter sales...

Eli Lilly Obliterates Sales Forecasts By $2 Billion, Shares Surge
The Wall Street Journal 8h
Eli Lilly Shares Jump as Mounjaro, Zepbound Fuel Massive Growth

Eli Lilly released its new weight-loss pill Foundayo this month. Eli Lilly / Handout / Reuters Booming sales of weight-loss shots fueled strong revenue and pro...

Eli Lilly Shares Jump as Mounjaro, Zepbound Fuel Massive Growth
Nasdaq 8h
Eli Lilly Beats Q1 Earnings and Revenue Estimates

Eli Lilly (LLY) came out with quarterly earnings of $8.55 per share, beating the Zacks Consensus Estimate of $7.06 per share. This compares to earnings of $3.34...

Eli Lilly Beats Q1 Earnings and Revenue Estimates
CNBC 9h
Eli Lilly CEO David Ricks on Q1 results, Zepbound-Mounjaro sales growth and launch of Foundayo pill - CNBC

...

Eli Lilly CEO David Ricks on Q1 results, Zepbound-Mounjaro sales growth and launch of Foundayo pill - CNBC

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.